Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23N5O4 |
Molecular Weight | 361.3956 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)C2=CC=C(C=C2)C(N)=N
InChI
InChIKey=VJDOPFARMOLELX-ZDUSSCGKSA-N
InChI=1S/C17H23N5O4/c1-2-26-14(23)7-9-20-17(25)21-13-8-10-22(16(13)24)12-5-3-11(4-6-12)15(18)19/h3-6,13H,2,7-10H2,1H3,(H3,18,19)(H2,20,21,25)/t13-/m0/s1
Molecular Formula | C17H23N5O4 |
Molecular Weight | 361.3956 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Orbofiban was developed as an orally active glycoprotein IIb/IIIa antagonist. By 2001, this drug had progressed to phase III clinical trials. Unfortunately, was found that orbofiban induced thrombocytopenia and thrombosis. In addition, despite no significant excess risk of intracranial hemorrhage, orbofiban was not effective in preventing ischemic stroke or transient ischemic attack. Besides, the use of this drug had led to an increase in mortality. Based on all these results further development of this drug was discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17008974
Unknown
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:31:29 GMT 2023
by
admin
on
Sat Dec 16 16:31:29 GMT 2023
|
Record UNII |
FGJ53JS7PT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
178080
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
FGJ53JS7PT
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
163250-90-6
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL64706
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
DTXSID20167543
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
SUB09455MIG
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
7508
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
C170261
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
C120234
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY | |||
|
100000083344
Created by
admin on Sat Dec 16 16:31:30 GMT 2023 , Edited by admin on Sat Dec 16 16:31:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|